Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Autoimmune Diseases Research Model Developed to Clarify Antibody Mechanisms

By BiotechDaily International staff writers
Posted on 21 Jul 2013
Canadian scientists have devised a unique research model for the study of autoimmune diseases. The Montréal scientists are the first to find an approach to better understand two significant processes that enhance the quality of antibodies.

This study, conducted by researchers from the l'Institut de Recherches Cliniques de Montréal (IRCM; QB, Canada), led by Dr. Javier M. Di Noia in the immunity and viral infections research division, was published in the June 15, 2013, issue of the Journal of Immunology.

Dr. Di Noia’s team is evaluating B cells, a group of white blood cells known as lymphocytes whose major task is to make antibodies to fight against antigens. “Our project focused on two mechanisms that produce this wide variety of antibodies,” said Dr. Di Noia, director of the mechanisms of genetic diversity research unit at the IRCM. “Because both processes are initiated by the same enzyme known as AID [activation-induced deaminase], it had previously been very difficult to study them separately. We were able to identify, for the first time, a mouse model in which the mechanisms could be analyzed independently during an acute immune response.”

The two processes being studied are known as class switching and affinity maturation. Class switching is the mechanism that allows a B cell to generate diverse classes of antibodies, so that a single antibody can be used by several different parts of the immune system. Affinity maturation, on the other hand, is the process by which B cells produce antibodies with increasingly stronger bonds to antigens during an immune response.

“Since eliminating AID would in turn completely eliminate affinity maturation and class switching, we focused on an enzyme called UNG, which is also involved in both processes,” added Astrid Zahn, research associate in Dr. Di Noia’s laboratory and first author of the study. “When we analyzed mice lacking the UNG [uracil-DNA glycosylase] gene, we found that affinity maturation was normal but class switching was strongly reduced during acute immune responses, such as the response to immunization and against a viral infection.”

“While over 100 AID-deficient patients have been identified, it is striking that only a handful of patients are known to be UNG-deficient,” explained Dr. Zahn. “Our study, which shows that chronic antibody responses [those to environmental antigens] remain nearly normal without UNG, can explain why most UNG-deficient individuals are not detected among immunodeficient patients. Nevertheless, because we also found that acute antibody responses were significantly affected, we suspect that UNG-deficient people will, for example, respond very poorly to vaccination. In addition, as this work was conducted as part of a larger ongoing investigation of the complex relationship between AID and UNG, we believe that UNG might possibly act as a tumor-suppressor in B-cell lymphomas.”

“Until now, it was difficult to study the relative importance of class switching and affinity maturation, and the impact of these two mechanisms on immune responses,” concluded Dr. Di Noia. “Our study provides a novel model to study the contribution of these mechanisms in certain autoimmune diseases such as lupus and rheumatoid arthritis, or some infections like influenza.”

Related Links:

l'Institut de Recherches Cliniques de Montréal



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.